---
slug: ara-290-metformin
title: "ara 290 metformin"
kind: standard
status: published
hash: 51a80a53a3d0aa1e577a7beff5b28acbe809b9150b232cadcd6971f3bb51be41
created: 2026-08-08T04:22:59.977Z
updated: 2026-10-08T11:31:11.444Z
summary: "metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits. Studied for nerve repair and small-fiber regeneration"
tags: ["peptide"]
above: []
below: []
adjacent: []
nested: []
---
# ara 290 metformin

*metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits. Studied for nerve repair and small-fiber regeneration*

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-07-17T02:38:13.721Z",
  "register": "standard",
  "category": null
}
```